Yeah, honestly, whether it helps COVID-19, or not, any attention is probably good attention, for RVX pps. RVX Corp doesn't seem very focused or maybe even very interested in increasing knowledge and awareness of apabetalone though (nor pps) at the moment ... except in academic, regulatory, and perhaps BP circles. It's not necessarily a bad thing, especially if something is cooking. That's why I keep re-focusing on transactional benefits, where the tea leaves seem to be pointing, rather than homegrown organic pps growth.

Just think a lot of information and news simply has to start flowing here in the next 30-90 days, following NKF and that embargo, and the ensuing and imminent regulatory milestones/directions. We just don't know though.

But ... feeling good in my "gut", and thinking there are good things ahead, and for a lot more than $6 pps. jmho

glta